R&D Trends

Denovo Biopharma licenses late-stage neuroscience drug from Eli Lilly

Wednesday, March 4, 2015 01:15 PM

Denovo Biopharma, a privately held biotechnology company based in San Diego, has exclusively licensed Pomaglumetad Methionil (mGlu2/3 receptor agonist), a late-stage neuroscience drug, from Eli Lilly. Denovo gains all rights to develop, manufacture and commercialize pomaglumetad globally, including transfer of all intellectual property and other rights, data and information. Lilly has an option to re-acquire pomaglumetad upon a successful clinical trial, for predetermined undisclosed financial terms.

More... »

Quest Diagnostics

Kite Pharma expands R&D collaboration with National Cancer Institute

Wednesday, March 4, 2015 01:11 PM

Kite Pharma, a clinical stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products for the treatment of cancer based in Santa Monica, Calif., has amended its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).

More... »


CCFA, University of Pennsylvania, Nestlé collaborate on IBD study

Wednesday, March 4, 2015 01:09 PM

The Crohn's & Colitis Foundation of America (CCFA) has entered into a research partnership with the Perelman School of Medicine at the University of Pennsylvania and Nestlé Health Science to study the effects of diet on gut bacteria. The study is part of a major CCFA effort to develop new treatments targeting the gut microbiome—the "ecosystem" of microbes populating the intestines—linked to the development of inflammatory bowel diseases (IBD).

More... »

Bristol-Myers Squibb, Bavarian Nordic ink agreement for PROSTVAC

Wednesday, March 4, 2015 01:06 PM

Bristol-Myers Squibb has signed an exclusive option to license and commercialize PROSTVAC, Bavarian Nordic's investigational phase III prostate-specific antigen (PSA)-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

More... »

Blueprint Medicines, Alexion Pharmaceuticals ink $265M deal

Wednesday, March 4, 2015 12:55 PM

Blueprint Medicines is collaborating with Alexion Pharmaceuticals to discover, develop and commercialize novel drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease.

More... »

AstraZeneca, Cambridge Judge Business School collaborate to support biotech startups

Wednesday, March 4, 2015 09:35 AM

AstraZeneca and the University of Cambridge Judge Business School have announced an agreement to deliver a new “Accelerate Cambridge Life Sciences” program at the business school that will identify, train and mentor start-up ventures in the life sciences.

More... »

Roche, BioMed X collaborate to develop nanomaterial-based biosensors

Thursday, February 26, 2015 03:30 PM

Roche and BioMed X, a collaboration model at the interface between academia and industry based in Heidelberg, Germany, have entered into a collaboration agreement to establish a research group focusing on the development of a novel sensor technology platform based on new nanomaterials such as graphene.

More... »

Recursion Pharmaceuticals wins $1.5M NIH grant for rare diseases

Thursday, February 26, 2015 03:28 PM

Recursion Pharmaceuticals, an emerging biotech company founded in 2013 based on technology developed at the University of Utah, has been awarded $1.46 million from the NIH via the National Center for Accelerating Translational Sciences (NCATS). Just over half of the award is available in the first year; the rest will come through in year two pending availability of funds and project progress. The award will support the further development of Recursion’s Drug Screening Platform for hundreds of rare genetic diseases.

More... »

Report: Global oncology drugs market is expected to reach $111.9B by 2020

Wednesday, February 25, 2015 11:31 AM

The global oncology market is forecasted to reach $111.9 billion by 2020, registering a CAGR of 7.1% from 2014 to 2020, according to a new report by Allied Market Research, titled Global Oncology/Cancer Drugs Market—Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2013-2020.

More... »

Orca Pharmaceuticals, AstraZeneca partner to treat autoimmune disease

Wednesday, February 25, 2015 11:23 AM

Orca Pharmaceuticals, a U.K. based biopharmaceutical company, and AstraZeneca have announced a three-year collaboration to develop inhibitors of retinoic acid–related orphan nuclear receptor gamma (RORγ). Inhibitors of this receptor are believed to have potential against a wide range of autoimmune diseases for which there currently is no safe, orally available and effective treatment.

More... »

CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs